Research subsite
Team
Drug Discovery Unit projects
Key collaborators
Kirill Alexandrov, Cell Biology and Molecular Medicine – Institute for Molecular Bioscience, Queensland (ARC-linkage grant-funded)
Pilar Blancafort, Cancer Epigenetics – Harry Perkins Institute of Medical Resarch, Perth
Doug Fairlie, Cell Death & Survival Group – Olivia Newton-John Cancer Research Institute, Melbourne (NHMRC grant-funded)
Sue Fletcher and Steve Wilton, Centre for Comparative Genomics – Murdoch University, Perth
David Frank, Medical Oncology – Dana-Farber Cancer Institute, Boston
Yann Gambin, Single Molecule Science – University NSW, Sydney (ARC-linkage grant-funded)
David Lane, A STAR – Singapore
Arturo Sala, Environment and Health – Brunel University, London
Jason Waithman, Tumour Immunology Unit – Telethon Kids Institute, Perth
Genentech – San Francisco
Phoremost – Cambridge UK
Reports and Findings
A platform for discovery of functional cell-penetrating peptides for efficient multi-cargo intracellular delivery
This report thus establishes a discovery platform for identifying novel, functional CPPs to expand the delivery landscape of druggable intracellular targets for biological therapeutics
Published research Drug Discovery Unitβ-Lactamase Tools for Establishing Cell Internalization and Cytosolic Delivery of Cell Penetrating Peptides
The β-lactamase assays provide compatible tools for functional characterization of CPP activity and the delivery of biological cargos into cells
Published research Drug Discovery UnitPhylomer Libraries: A Rich Source of Peptide Hits in Phenotypic and Target Directed Screens
The poor hit rates associated with conventional random peptide libraries present formidable challenges in genetic screening formats with limited throughput.
Published research Drug Discovery UnitStructure-diverse Phylomer libraries as a rich source of bioactive hits from phenotypic and target directed screens against intracellular proteins
Phylomer libraries are being increasingly used in applications such as phenotypic screening where the numbers of peptides which can be feasibly screened is limited
Published research Drug Discovery Unit